BRAF and melanoma: The emerging importance of targeted therapy approaches in oncology together with the established role of BRAF mutation specific small molecule inhibitor treatment in metastasized melanoma have laid the foundation upon which the transfer to other tumor entities with BRAF alterations can be built.